Announcements Trials
Browse Landscape

Phase

Phase 2 91Phase 1 39Phase 1/2 34Phase 3 25Phase EARLY_PHASE1 7Phase 4 6Phase NA 2Phase 2/3 1

Status

Recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Neoplasm Metastasis 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × abemaciclib × Clear all
NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

NCT06169371 2026-01-14

BRE-09

University of Illinois at Chicago

Phase 4 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

University of Ulm

Phase 4 Recruiting
300 enrolled
Breast

Breast Neoplasms

NCT04707196 2023-11-24

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Eli Lilly and Company

Phase 4 Completed
200 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Eli Lilly and Company

Phase 4 Terminated
4 enrolled 9 charts
Breast

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡